Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.

Zhang Y, Wester L, He J, Geiger T, Moerkens M, Siddappa R, Helmijr JA, Timmermans MM, Look MP, van Deurzen CHM, Martens JWM, Pont C, de Graauw M, Danen EHJ, Berns EMJJ, Meerman JHN, Jansen MPHM, van de Water B.

Oncogene. 2018 Apr;37(14):1869-1884. doi: 10.1038/s41388-017-0027-9. Epub 2018 Jan 22.

PMID:
29353882
2.

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer.

De Marchi T, Timmermans MA, Sieuwerts AM, Smid M, Look MP, Grebenchtchikov N, Sweep FCGJ, Smits JG, Magdolen V, van Deurzen CHM, Foekens JA, Umar A, Martens JW.

Sci Rep. 2017 May 18;7(1):2099. doi: 10.1038/s41598-017-02296-w.

3.

Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.

van Dessel LF, Beije N, Helmijr JC, Vitale SR, Kraan J, Look MP, de Wit R, Sleijfer S, Jansen MP, Martens JW, Lolkema MP.

Mol Oncol. 2017 Mar;11(3):295-304. doi: 10.1002/1878-0261.12037. Epub 2017 Feb 22.

4.

Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer.

Dalm SU, Schrijver WA, Sieuwerts AM, Look MP, Ziel-van der Made AC, de Weerd V, Martens JW, van Diest PJ, de Jong M, van Deurzen CH.

PLoS One. 2017 Jan 20;12(1):e0170536. doi: 10.1371/journal.pone.0170536. eCollection 2017.

5.

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA.

Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19.

6.

Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients.

Liu NQ, De Marchi T, Timmermans A, Trapman-Jansen AM, Foekens R, Look MP, Smid M, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Foekens JA, Martens JW, Umar A.

Sci Rep. 2016 Aug 25;6:32027. doi: 10.1038/srep32027.

7.

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.

Liu J, Sieuwerts AM, Look MP, van der Vlugt-Daane M, Meijer-van Gelder ME, Foekens JA, Hollestelle A, Martens JW.

PLoS One. 2016 Aug 23;11(8):e0161731. doi: 10.1371/journal.pone.0161731. eCollection 2016.

8.

LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.

Ramirez-Ardila DE, Ruigrok-Ritstier K, Helmijr JC, Look MP, van Laere S, Dirix L, Berns EM, Jansen MP.

Mol Oncol. 2016 Oct;10(8):1363-73. doi: 10.1016/j.molonc.2016.07.004. Epub 2016 Jul 25.

9.

Opioid treatment failure in cancer patients: the role of clinical and genetic factors.

Oosten AW, Matic M, van Schaik RH, Look MP, Jongen JL, Mathijssen RH, van der Rijt CC.

Pharmacogenomics. 2016 Aug;17(13):1391-403. doi: 10.2217/pgs-2016-0082. Epub 2016 Jul 29. Erratum in: Pharmacogenomics. 2017 May;18(7):743-748.

PMID:
27472837
10.

SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy.

van der Willik KD, Timmermans MM, van Deurzen CH, Look MP, Reijm EA, van Zundert WJ, Foekens R, Trapman-Jansen AM, den Bakker MA, Westenend PJ, Martens JW, Berns EM, Jansen MP.

Am J Cancer Res. 2016 Jan 15;6(2):270-84. eCollection 2016.

11.

Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis.

Weerts MJ, Sieuwerts AM, Smid M, Look MP, Foekens JA, Sleijfer S, Martens JW.

Oncotarget. 2016 May 17;7(20):29166-76. doi: 10.18632/oncotarget.8688.

12.

GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.

Liu J, Prager-van der Smissen WJ, Look MP, Sieuwerts AM, Smid M, Meijer-van Gelder ME, Foekens JA, Hollestelle A, Martens JW.

Cancer Lett. 2016 Jun 28;376(1):104-9. doi: 10.1016/j.canlet.2016.03.038. Epub 2016 Mar 24.

13.

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.

De Marchi T, Timmermans AM, Smid M, Look MP, Stingl C, Opdam M, Linn SC, Sweep FC, Span PN, Kliffen M, van Deurzen CH, Luider TM, Foekens JA, Martens JW, Umar A.

Oncotarget. 2016 Jan 19;7(3):3098-110. doi: 10.18632/oncotarget.6521.

14.

4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.

De Marchi T, Liu NQ, Stingl C, Timmermans MA, Smid M, Look MP, Tjoa M, Braakman RB, Opdam M, Linn SC, Sweep FC, Span PN, Kliffen M, Luider TM, Foekens JA, Martens JW, Umar A.

Mol Oncol. 2016 Jan;10(1):24-39. doi: 10.1016/j.molonc.2015.07.004. Epub 2015 Aug 7.

15.

Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.

Dalm SU, Sieuwerts AM, Look MP, Melis M, van Deurzen CH, Foekens JA, de Jong M, Martens JW.

J Nucl Med. 2015 Oct;56(10):1487-93. doi: 10.2967/jnumed.115.160739. Epub 2015 Aug 6.

16.

Multivariate meta-analysis of individual participant data helped externally validate the performance and implementation of a prediction model.

Snell KI, Hua H, Debray TP, Ensor J, Look MP, Moons KG, Riley RD.

J Clin Epidemiol. 2016 Jan;69:40-50. doi: 10.1016/j.jclinepi.2015.05.009. Epub 2015 May 16.

17.

Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant.

van Roosmalen W, Le Dévédec SE, Golani O, Smid M, Pulyakhina I, Timmermans AM, Look MP, Zi D, Pont C, de Graauw M, Naffar-Abu-Amara S, Kirsanova C, Rustici G, Hoen PA, Martens JW, Foekens JA, Geiger B, van de Water B.

J Clin Invest. 2015 Apr;125(4):1648-64. doi: 10.1172/JCI74440. Epub 2015 Mar 16.

18.

Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.

Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A, Peeters DJ, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, Stouthard JM, Kehrer DF, Look MP, Smid M, Gratama JW, Foekens JA, Martens JW, Sleijfer S.

Ann Oncol. 2015 Mar;26(3):510-6. doi: 10.1093/annonc/mdu557. Epub 2014 Dec 3.

PMID:
25471333
19.

Growth and metastatic behavior of molecularly well-characterized human breast cancer cell lines in mice.

Riaz M, Setyono-Han B, Timmermans MA, Trapman AM, Bolt-de Vries J, Hollestelle A, Janssens RC, Look MP, Schutte M, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2014 Nov;148(1):19-31. doi: 10.1007/s10549-014-3142-0. Epub 2014 Sep 30.

PMID:
25266129
20.

High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.

Reijm EA, Timmermans AM, Look MP, Meijer-van Gelder ME, Stobbe CK, van Deurzen CH, Martens JW, Sleijfer S, Foekens JA, Berns PM, Jansen MP.

Ann Oncol. 2014 Nov;25(11):2185-90. doi: 10.1093/annonc/mdu391. Epub 2014 Sep 5.

PMID:
25193989
21.

Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.

Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, Heideman MR, Jacobs H, Wessels L, Leyland-Jones B, Gray KP, Foekens JA, Harris RS, Martens JW.

Horm Cancer. 2014 Dec;5(6):405-13. doi: 10.1007/s12672-014-0196-8. Epub 2014 Aug 15.

22.
23.

Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response.

Liu NQ, De Marchi T, Timmermans AM, Beekhof R, Trapman-Jansen AM, Foekens R, Look MP, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Debets R, Martens JW, Foekens JA, Umar A.

Mol Cell Proteomics. 2014 Jul;13(7):1814-27. doi: 10.1074/mcp.M113.037176. Epub 2014 Apr 17.

24.

LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.

Nagelkerke A, Sieuwerts AM, Bussink J, Sweep FC, Look MP, Foekens JA, Martens JW, Span PN.

Endocr Relat Cancer. 2014 Jan 16;21(1):101-12. doi: 10.1530/ERC-13-0183. Print 2014 Feb.

PMID:
24434718
25.

Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.

Liu NQ, Stingl C, Look MP, Smid M, Braakman RB, De Marchi T, Sieuwerts AM, Span PN, Sweep FC, Linderholm BK, Mangia A, Paradiso A, Dirix LY, Van Laere SJ, Luider TM, Martens JW, Foekens JA, Umar A.

J Natl Cancer Inst. 2014 Feb;106(2):djt376. doi: 10.1093/jnci/djt376. Epub 2014 Jan 7.

26.

CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations.

Redis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, Zhang X, de Weerd V, Shimizu M, Ling H, Buiga R, Pop V, Irimie A, Fodde R, Bedrosian I, Martens JW, Foekens JA, Berindan-Neagoe I, Calin GA.

Oncotarget. 2013 Oct;4(10):1748-62.

27.

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.

Ramirez-Ardila DE, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, van Laere S, Dirix L, Sweep FC, Span PN, Linn SC, Foekens JA, Sleijfer S, Berns EM, Jansen MP.

Breast Cancer Res Treat. 2013 May;139(1):39-49. doi: 10.1007/s10549-013-2529-7. Epub 2013 Apr 17.

PMID:
23592373
28.

KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.

Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, Germain D, Burstein D, Kirschenbaum A, DiFeo A, Foekens JA, Narla G.

Sci Transl Med. 2013 Jan 23;5(169):169ra12. doi: 10.1126/scitranslmed.3004688.

29.

High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.

Riaz M, Sieuwerts AM, Look MP, Timmermans MA, Smid M, Foekens JA, Martens JW.

Breast Cancer Res. 2012 Sep 11;14(5):R123. doi: 10.1186/bcr3317.

30.

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.

Godinho MF, Wulfkuhle JD, Look MP, Sieuwerts AM, Sleijfer S, Foekens JA, Petricoin EF 3rd, Dorssers LC, van Agthoven T.

Br J Cancer. 2012 Sep 4;107(6):947-55. doi: 10.1038/bjc.2012.351. Epub 2012 Aug 14.

31.

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.

Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodríguez-González FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2012 Jun;133(3):937-47. doi: 10.1007/s10549-011-1877-4. Epub 2011 Nov 18.

32.

Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.

Riaz M, Berns EM, Sieuwerts AM, Ruigrok-Ritstier K, de Weerd V, Groenewoud A, Uitterlinden AG, Look MP, Klijn JG, Sleijfer S, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2012 Jun;133(3):843-51. doi: 10.1007/s10549-011-1663-3. Epub 2011 Jul 12.

PMID:
21748294
33.

Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.

Sieuwerts AM, Ansems M, Look MP, Span PN, de Weerd V, van Galen A, Foekens JA, Adema GJ, Martens JW.

Breast Cancer Res. 2010;12(6):R103. doi: 10.1186/bcr2786. Epub 2010 Dec 1.

34.

Personal genetics: regulatory framework in Europe from a service provider's perspective.

Grimaldi KA, Look MP, Scioli GA, Clavero JC, Marinos S, Tagaris T.

Eur J Hum Genet. 2011 Apr;19(4):382-8. doi: 10.1038/ejhg.2010.189. Epub 2010 Dec 1. Review.

35.

Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.

Godinho MF, Sieuwerts AM, Look MP, Meijer D, Foekens JA, Dorssers LC, van Agthoven T.

Br J Cancer. 2010 Oct 12;103(8):1284-91. doi: 10.1038/sj.bjc.6605884. Epub 2010 Sep 21.

36.

Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus.

Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S, Kostic JP, Fackenthal JD, Huo D, Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, Wang X, Look MP, Sieuwerts AM, Martens JW, Pajares I, Garcia-Prats MD, Ramon-Cajal JM, de Juan A, Panadero A, Ortega E, Aben KK, Vermeulen SH, Asadzadeh F, van Engelenburg KC, Margolin S, Shen CY, Wu PE, Försti A, Lenner P, Henriksson R, Johansson R, Enquist K, Hallmans G, Jonsson T, Sigurdsson H, Alexiusdottir K, Gudmundsson J, Sigurdsson A, Frigge ML, Gudmundsson L, Kristjansson K, Halldorsson BV, Styrkarsdottir U, Gulcher JR, Hemminki K, Lindblom A, Kiemeney LA, Mayordomo JI, Foekens JA, Couch FJ, Olopade OI, Gudbjartsson DF, Thorsteinsdottir U, Rafnar T, Johannsson OT, Stefansson K.

PLoS Genet. 2010 Jul 22;6(7):e1001029. doi: 10.1371/journal.pgen.1001029.

37.

MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer.

Rodríguez-González FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW, Foekens JA.

Breast Cancer Res Treat. 2011 May;127(1):43-51. doi: 10.1007/s10549-010-0940-x. Epub 2010 May 19.

PMID:
20490652
38.

Correspondence (letter to the editor): Disputed meta-analyses.

Look MP.

Dtsch Arztebl Int. 2010 Apr;107(13):224-5; author reply 225-6. doi: 10.3238/arztebl.2010.0224b. Epub 2010 Apr 2. No abstract available.

39.

Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.

Reijm EA, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, van Gelder ME, Sieuwerts AM, Sleijfer S, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2011 Jan;125(2):387-94. doi: 10.1007/s10549-010-0836-9. Epub 2010 Mar 20.

PMID:
20306127
40.

Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study.

Hsieh SM, Look MP, Sieuwerts AM, Foekens JA, Hunter KW.

Breast Cancer Res. 2009;11(5):R75. doi: 10.1186/bcr2412.

41.
42.

Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer.

Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, Pasa-Tolić L.

Mol Cell Proteomics. 2009 Jun;8(6):1278-94. doi: 10.1074/mcp.M800493-MCP200. Epub 2009 Mar 27.

43.

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.

van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC.

J Clin Oncol. 2009 Feb 1;27(4):542-9. doi: 10.1200/JCO.2008.17.1462. Epub 2008 Dec 15.

PMID:
19075277
44.

Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.

Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM.

Clin Cancer Res. 2008 Sep 1;14(17):5555-64. doi: 10.1158/1078-0432.CCR-08-0555.

45.

Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.

Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Wiemer EA, Martens JW.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13021-6. doi: 10.1073/pnas.0803304105. Epub 2008 Aug 28.

46.

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Helleman J, Sleijfer S, Klijn JG, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2009 Jul;116(2):263-71. doi: 10.1007/s10549-008-0125-z. Epub 2008 Jul 16.

PMID:
18629630
47.

Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.

Meijer D, Sieuwerts AM, Look MP, van Agthoven T, Foekens JA, Dorssers LC.

Endocr Relat Cancer. 2008 Mar;15(1):101-11. doi: 10.1677/ERC-07-0080.

PMID:
18310279
48.

TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.

Meijer D, Jansen MP, Look MP, Ruigrok-Ritstier K, van Staveren IL, Sieuwerts AM, van Agthoven T, Foekens JA, Dorssers LC, Berns EM.

Breast Cancer Res Treat. 2009 Jan;113(2):253-60. doi: 10.1007/s10549-008-9934-3. Epub 2008 Feb 26.

PMID:
18299979
49.

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.

Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, Magdolen V, Portengen H, Look MP, Klijn JG, Lesche R, Schmitt M, Maier S, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2008 Oct;111(3):429-37. Epub 2007 Oct 28.

PMID:
17965955
50.

Polymorphic variations in exon 10 of the luteinizing hormone receptor: functional consequences and associations with breast cancer.

Piersma D, Verhoef-Post M, Look MP, Uitterlinden AG, Pols HA, Berns EM, Themmen AP.

Mol Cell Endocrinol. 2007 Sep 30;276(1-2):63-70. Epub 2007 Jul 17.

PMID:
17709176

Supplemental Content

Support Center